Program
bicalutamide
Also written as “Bicalutamide”, “ICI176,334-1” and “Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)”.
Its studies are mostly in Prostatic Neoplasms · Lower Urinary Tract Symptoms · Puberty, Precocious · Gynecomastia, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 130 open or running | phase 4since Oct 26, 2005 | Oct 16, 2004 | none ahead |
| Alessa Therapeutics | 21 open or running | phase 1since Feb 12, 2020 | Feb 12, 2020 | Apr 24, 2027phase 1 · NCT04943536 |
| Kremers Urban Development | 20 open or running | phase 1since Dec 23, 2009 | Dec 23, 2009 | none ahead |
| Novartis | 20 open or running | phase 1since Aug 13, 2009 | Aug 13, 2009 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 1since Sep 8, 2009 | Sep 8, 2009 | none ahead |
Also a collaborator on its studies: AbbVie.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Oct 16, 2004.
- Oct 26, 2005Phase 4 study in Prostatic NeoplasmsAstraZeneca · NCT00255268 · 15 enrolled · Mexico
- Dec 28, 2007Phase 4 study in Prostatic NeoplasmsAstraZeneca · NCT00590213 · 125 enrolled · Turkey
- Mar 12, 2008Phase 2 study in GynecomastiaAstraZeneca · NCT00637871
- Apr 7, 2008Phase 3 study in Prostatic NeoplasmsAstraZeneca · NCT00657904 · 3,618 enrolled · United States, Canada
- May 2, 20082 phase 3 studies in Prostatic NeoplasmsAstraZeneca · NCT00673205, NCT00672282
- Feb 18, 2009Phase 3 study in Prostatic NeoplasmsAstraZeneca · NCT00846976 · 101 enrolled · United States
- Aug 13, 2009Novartis's first studies: 2 phase 1 studies in Prostatic NeoplasmsNew to NovartisNovartis · NCT00960310, NCT00959335
- Sep 8, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00973050, NCT00972855
- Dec 23, 2009Kremers Urban Development's first study: phase 1 study in BioequivalencyNew to Kremers Urban DevelopmentKremers Urban Development · NCT01039233 · 60 enrolled · Canada
- Jan 7, 2010Phase 1 study in HealthyKremers Urban Development · NCT01044706 · 60 enrolled · Canada
- Aug 11, 20114 phase 1 studies in HealthyAstraZeneca · NCT01415791, NCT01415778, NCT01416883 and 1 more
- Mar 21, 2019Phase 4 study in Advanced Prostate CancerAstraZeneca · NCT03971110 · 9 enrolled · China
- Feb 12, 2020Alessa Therapeutics's first study: phase 1 study in Lower Urinary Tract SymptomsNew to Alessa TherapeuticsAlessa Therapeutics · NCT04284761 · 17 enrolled · United States, Australia, New Zealand
- Jun 15, 2021Phase 1 study in Prostate AdenocarcinomaAlessa Therapeutics · NCT04943536 · 20 enrolled · United States
Ahead
- Apr 24, 2027Primary completion: phase 1 study in Prostate AdenocarcinomaAlessa Therapeutics · NCT04943536
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT04943536Prostate Adenocarcinoma · United States | 1 | Active, not recruiting | Alessa Therapeutics | Apr 24, 2027 | 20 |
| NCT04284761Lower Urinary Tract Symptoms · United States, Australia, New Zealand | 1 | Completed | Alessa Therapeutics | May 3, 2023 | 17 |
| NCT03971110Advanced Prostate Cancer · China | 4 | Terminated | AstraZeneca | Nov 9, 2022 | 9 |
| NCT01416883Healthy | 1 | Terminated | AstraZeneca | Aug 2010 | 8 |
| NCT01416870Healthy | 1 | Terminated | AstraZeneca | Nov 2010 | 102 |
| NCT01415791Healthy | 1 | Completed | AstraZeneca | Sep 2011 | 8 |
| NCT01415778Healthy | 1 | Completed | AstraZeneca | Nov 2011 | 48 |
| NCT01044706Healthy · Canada | 1 | Completed | Kremers Urban Development | Jul 2005 | 60 |
| NCT01039233Bioequivalency · Canada | 1 | Completed | Kremers Urban Development | Jun 2005 | 60 |
| NCT00973050Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Sep 2003 | 60 |
| NCT00972855Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Sep 2003 | 60 |
| NCT00960310Prostatic Neoplasms | 1 | Completed | Novartis | Jun 2006 | 36 |
| NCT00959335Prostatic Neoplasms | 1 | Completed | Novartis | Aug 2006 | 36 |
| NCT00846976Prostatic Neoplasms · United States | 3 | Completed | AstraZeneca | Jun 2013 | 101 |
| NCT00673205Prostatic Neoplasms · Australia, Austria, Belgium and more | 3 | Completed | AstraZeneca | Aug 2008 | 3,588 |
| NCT00672282Prostatic Neoplasms · Denmark, Finland, Norway and more | 3 | Completed | AstraZeneca | 1,218 | |
| NCT00657904Prostatic Neoplasms · United States, Canada | 3 | Completed | AstraZeneca | Jul 2008 | 3,618 |
| NCT00637871Gynecomastia | 2 | Completed | AstraZeneca | Jun 2005 | |
| NCT00590213Prostatic Neoplasms · Turkey | 4 | Completed | AstraZeneca | 125 | |
| NCT00255268Prostatic Neoplasms · Mexico | 4 | Withdrawn | AstraZeneca | 15 | |
| NCT00094328Puberty, Precocious · United States, Canada, France and more | 2 | Completed | AstraZeneca | May 22, 2008 | 14 |
How it is read
Names in the registry
- “Bicalutamide”, 9 entries
- “ICI176,334-1”, 4 entries
- “bicalutamide”, 2 entries
- “Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)”, 2 entries
- “Casodex 80 mg tablet”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 10 studies
- Lower Urinary Tract Symptoms, 1 study
- Puberty, Precocious, 1 study
- Gynecomastia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.